Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 2
2012 2
2013 1
2014 4
2016 2
2017 4
2019 2
2020 8
2021 6
2022 4
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI; RAISE Study Team. Howard JF Jr, et al. Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7. Lancet Neurol. 2023. PMID: 37059508 Clinical Trial.
Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Uzawa A, et al. Among authors: kubota t. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):467-473. doi: 10.1136/jnnp-2022-330519. Epub 2023 Jan 24. J Neurol Neurosurg Psychiatry. 2023. PMID: 36693723
Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan.
Yasuda M, Uzawa A, Kuwabara S, Suzuki S, Akamine H, Onishi Y, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Yasuda M, et al. Among authors: kubota t. J Neuroimmunol. 2023 Dec 15;385:578241. doi: 10.1016/j.jneuroim.2023.578241. Epub 2023 Nov 7. J Neuroimmunol. 2023. PMID: 37952282
Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Uzawa A, et al. Among authors: kubota t. Neurotherapeutics. 2023 Mar;20(2):518-523. doi: 10.1007/s13311-022-01335-3. Epub 2023 Jan 6. Neurotherapeutics. 2023. PMID: 36607596 Free PMC article.
Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan.
Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, Kubota T, Samukawa M, Ishizuchi K, Tokuyasu D, Handa H, Yasuda M, Kawaguchi N, Kimura T, Suzuki Y, Sugimoto T, Minami N, Takahashi MP, Murai H, Utsugisawa K. Suzuki S, et al. Among authors: kubota t. Neurol Clin Pract. 2024 Jun;14(3):e200276. doi: 10.1212/CPJ.0000000000200276. Epub 2024 Mar 25. Neurol Clin Pract. 2024. PMID: 38544885 Free PMC article.
Ethylene signaling mediates host invasion by parasitic plants.
Cui S, Kubota T, Nishiyama T, Ishida JK, Shigenobu S, Shibata TF, Toyoda A, Hasebe M, Shirasu K, Yoshida S. Cui S, et al. Among authors: kubota t. Sci Adv. 2020 Oct 28;6(44):eabc2385. doi: 10.1126/sciadv.abc2385. Print 2020 Oct. Sci Adv. 2020. PMID: 33115743 Free PMC article.
45 results